Sanofi News

6-K: Sanofi and CD&R Close Opella Transaction, Create Global Consumer Healthcare Leader

Apr 30 14:51 ET

6-K: Dupixent Approved in the US as the First New Targeted Therapy in over a Decade for Chronic Spontaneous Urticaria

Apr 22 12:29 ET

6-K: Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Apr 16 09:18 ET

6-K: Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Apr 10 06:12 ET

6-K: Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Apr 4 08:44 ET

6-K: Dupixent Approved as the First-Ever Biologic Medicine in Japan for Patients with COPD and Qfitlia Approved as the First Therapy in the US to Treat Hemophilia A or B with or Without Inhibitors

Apr 2 06:16 ET

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 27 13:39 ET

6-K: Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis and Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Mar 26 11:57 ET

S-8 POS: S-8 POS

Mar 21 06:05 ET

6-K: Sanofi to Acquire Dren Bio's Bispecific Myeloid Cell Engager for Deep B-Cell Depletion, Broadening Immunology Pipeline

Mar 20 11:07 ET

6-K: Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Mar 10 12:23 ET

6-K: Sanofi Successfully Prices Eur 1.5 Billion of Bond Issue

Mar 6 10:25 ET

6-K: New Duvakitug Data Reinforce Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease and Sarclisa Approved in Japan for Patients with Newly Diagnosed Multiple Myeloma

Feb 28 06:15 ET

6-K: Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid and Sanofi and CD&R Sign Opella Share Purchase Agreement

Feb 20 12:22 ET

6-K: Update on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

Feb 13 12:24 ET

6-K: Execution of a Share Buyback Agreement for up to €2 Billion

Feb 7 11:15 ET

6-K: Sarclisa Is the First Anti-CD38 Treatment in Combination with Standard-of-Care VRd Approved in China for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant and Sanofi Announces Buy Back of Shares from L'Oréal

Feb 3 10:17 ET

6-K: Opella Reaches Study Milestone for Cialis and Sarclisa Approved in the EU as the First Anti-CD38 Therapy in Combination with Standard-of-Care VRd to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Jan 24 06:08 ET

6-K: New Sarclisa Subcutaneous Formulation Met Co-Primary Endpoints in the IRAKLIA Phase 3 Study in Multiple Myeloma and Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Jan 14 08:42 ET

6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines

Dec 23, 2024 14:11 ET